Silence Therapeutics plc Stock Analysis & AI Score
Silence Therapeutics plc (SLN) has an ST Score of 48.8 (C+), driven by its Forecast (A) and held back by its Profitability (D). Analysts rate it Buy with a $57.00 price target (+408.0% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Silence Therapeutics plc (SLN) has an ST Score of 48.8 (C+), driven by its Forecast (A) and held back by its Profitability (D). Analysts rate it Buy with a $57.00 price target (+408.0% upside).
- Strongest
- ForecastA
- Weakest
- ProfitabilityD
All factor grades
- ForecastA
- Financial StrengthB+
- MomentumB+
- ValuationC+
- GrowthC-
- ProfitabilityD
- Piotroski1/9
Contact
SLN stock: frequently asked questions
What is SLN's ST Score?
Silence Therapeutics plc (SLN) has an ST Score of 48.8 (C+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is SLN a buy, hold, or sell?
Analysts rate SLN a Buy, with a price target of $57.00 (+408.0% vs the current price). Our ST Score grades it C+ (48.8/100). The ST Score is a data-driven signal, not a recommendation.
What are SLN's factor grades?
Valuation C+, Profitability D, Financial Strength B+, Momentum B+, Growth C-, Forecast A.
What is SLN's valuation grade?
Silence Therapeutics plc (SLN) earns a valuation grade of C+, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is SLN's growth grade?
Silence Therapeutics plc (SLN) earns a growth grade of C-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is SLN's profitability grade?
Silence Therapeutics plc (SLN) earns a profitability grade of D, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is SLN's financial strength grade?
Silence Therapeutics plc (SLN) earns a financial strength grade of B+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for SLN?
The average analyst price target for Silence Therapeutics plc (SLN) is $57.00 from 5 analysts, which is +408.0% versus the recent price of $11.22.
What is SLN's Piotroski score?
Silence Therapeutics plc (SLN) has a Piotroski F-Score of 1 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.